Saccharomyces boulardii

(Hypoallergenic)

Item no. 71050
Available in bottles of 50 capsules

The Possible Benefits of Saccharomyces boulardii, a Dietary Supplement

- Can aggressively displace problematic yeast species in the GI tract
- Can help prevent post-antibiotic diarrhea
- Supports the establishment of friendly bacteria in the GI tract
- Has been shown to increase levels of secretory IgA and inactivate bacterial toxins
- Helps to restore nutrient absorption capacity to the small intestinal mucosa

Description

The gastrointestinal tract is not just an inert tube, but a complex micro–ecosystem in which the mucosal lining of the host coexists with billions of microorganisms that live on or attached to the lining. These probiotic (life-enhancing) bacteria are provided with shelter and support, and copious amounts of food substrates. The body benefits from the vitamins and other useful metabolic products these bacteria produce. Other, less beneficial micro-organisms are also present and compete with the probiotics. Dietary supplementation with potent probiotic cultures assists the host in maintaining a healthy probiotic balance.

When taken orally, Saccharomyces boulardii quickly becomes established, and "blooms" soon after supplementation has begun. It is a probiotic, non-colonizing yeast species closely related to Brewer's yeast and not related to the yeast group to which Candida belongs. It can aggressively displace problematic yeast species in the GI tract and has been used in Europe to prevent post antibiotic diarrhea.

Saccharomyces boulardii taken orally produces lactic acid and some B vitamins as it becomes established and crowds out the unfriendly strains of yeast. It is then eliminated after supplementation is stopped. During use, friendly probiotic bacteria are allowed to colonize in the GI tract supporting micro-ecology.

Saccharomyces boulardii has been shown to increase levels of secretory IgA and research has shown it to be effective against specific unfriendly microbes.

Each capsule contains:	Saccharomyces boulardii	3 Billion (150 mg)
Other ingredients:	Cellulose, stearic acid.	
Suggested Use:	As a dietary supplement, 1 to 3 capsule three times daily, preferably on an empty stomach, or as directed by a healthcare practitioner.	

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

January - 2003

References

Adam M, et al. Saccharomyces Boulardii : Multicentric Double Blind Controlled Trial. Medecine Et Chirurgie Digestives 1976;5(6):401-406.

Barbet F, et al. Probiotics prevent antibiotic-associated diarrhoea. Br Med J 324:1345-6, 8 Jun 2002.

Bassetti S, Frei R, Zimmerli W. Fungemia With Saccharomyces Cerevisiae After Treatment With Saccharomyces Boulardii. Am J Med 1998;105:71-2.

Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42: 2-7, 1988.

Bleichner G, Bléhaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tubefed patients. A multicenter, randomized double-blind placebo-controlled trial. Intens Care Med 23: 517-523, 1997.

Brandao R L, Castro I M, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol. 1998 Feb;64(2):564-8.

Buts J P, Bernasconi P, et al. Response Of Human and Rat Small Intestinal Mucosa To Oral Administrationof Saccharomyces Boulardii. Pediatr Research20(2):192-196, 1986.

Buts J P, Corthier G, Delmee M. Saccharomyces Boulardii For Clostridium Difficile Associated Enteropathies In Infants. Journal Of Pediatric Gastroenterology & Nutrition 1993;16:419-425.

Buts J P, De Keyser N, et al. Saccharomyces Boulardii Enhances Rat Intestinal Enzyme Expression By Endoluminal Release Of Polyamines. Pediatric Research36(4):522-527, 1994.

Buts J P, De Keyser N, et al. Saccharomyces Boulardii Upgrades Cellular Adaptation After Proximal Enterectomy In Rats. Gut 1999;45:89-96 89.

Buts J P, Vaerman J P, Bernasconi P. The Immunoprotective Role Of Saccharomyces Boulardii. Biology Italiani 6:39-42, 1990.

Buts J P, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35: 251-256, 1990.

Castagliuolo I, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.Infect Immun. 1999 Jan;67(1):302-7.

Cetina-Sauri J G, Sierra Basto G. Therapeutic Evaluation Of Saccharomyces Boulardii In Children With Acute Diarrhea. Annales De Pediatrie 1994;41(6):397-400.

Chapoy P. Treatment of acute diarrhea in infants: a control study of S. boulardii. Annales de Pediatrie, 1985.

Dias R S, et al. Protective effect of Saccharomyces boulardii against the cholera toxins in rats. Braz J Med Biol Res 28: 323-325, 1995.

Elmer G W, MartinS W, et al. Survival Of Saccharomyces Boulardii In The Rat Gastrointestinal Tract And Effects Of Dietary Fiber. Microbial Ecology In Health And Disease 11:29-34 (1999).

Elmer G W, et al. Behavior Of Saccharomyces Boulardii In Recurrent Clostridium Difficile Disease Patients. Aliment Pharmacol Ther 13:1663-1668 (1999).

Elmer G W, Mcfarland L V, Surawicz C M, Editors. Biotherapeutic Agents And Infectious Diseases. Humana Press (1999).

Elmer G W. Probiotics: Living Drugs. Am J Health-systems Pharmacy 58:1101-1107 (2001).

Golledge C L, Riley T V. "Natural" Therapy For Infectious Diseases. Med J Austral 1996;164:94-5 [Review].

Guslandi, M, Mezzi G, Sorghi M, Testoni P A. Saccharomyces Boulardii In Maintenance Treatment Of Crohn's Disease. Digestive Diseases And Sciences, Vol. 45, No. 7 (July 2000), Pp. 1462-1464.

Hafeez A, et al. The Efficacy Of Saccharomyces Boulardii In The Treatment Of Acute Watery Diarrhea In Children: A Multicentre Randomized Controlled Trial. JCPSP, Jul 2002, Volume 12, Number 07.

Hochter W, Chase D, Hagenhoff G. Saccharomyces Boulardii In Treatment Of Acute Adult Diarrhea. Efficacy And Tolerance Of Treatment. Munchener Medizinische Wochenschrift 1990;132(12):188-192.

Izadnia F, Wong CT, Kocoshis SA. Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile- induced colonic secretion in the rat. Dig Dis Sci 43: 2055-2060, 1998.

James J S. Diarrhea, And The Experimental Treatment Saccharomyces Boulardii. Aids Treat News 1995 Jun 2;(No 224):1-4.

Kimmey KB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 35: 897-901, 1990.

Kollaritsch H H, Kremsner P, Wiedermann G, Scheiner O. Prevention Of Traveller's Diarrhea: Comparison Of Different Non-Antibiotic Preparations. Travel Medicine International 1989:9-17.

Levy D, Stergachis A, et al. Antibiotics And Clostridium Difficile Diarrhea In The Ambulatory Setting. Clinical Therapeutics 22:91-102 (2000).

Line J E, Stern N J, Bailey J S, Cox N A. Saccharomyces Boulardii Treatment To Diminish Campylobacter And Salmonella In Poultry. United States Pat.# 6,010,695. 19.2000.

Loizeau E. Can Antibiotic-associated Diarrhea Be Prevented? Annales De Gastroenterologie Et D Hepatologie 1993;29(1):15-8.

Marandi S, De Keyser N, Hermans D, Chae Yhe,Lambotte L, Buts J P. Saccharomyces Boulardii upgrades Cellular Adaptation Following Proximal Enterectomy In Rats. Gastroenterology, Vol. 116, N°4 -part 2, G2382, 1999.

Mcfarland L V, Elmer G W. Pharmaceutical Probiotics For The Treatment Of Anaerobic And Other Infections. Anaerobe 3:73-78 (1997).

Mcfarland L V, Surawicz C M, et al. Prevention Of Beta-lactam-associated Diarrhea By Saccharomyces Boulardii Compared With Placebo. Am J Gastroenterol 1995 Mar;90(3):439-48.

Mcfarland L V, Surawicz C M, et al. A Randomized Placebo-controlled Trial Of Saccharomyces Boulardii In Combination With Standard Antibiotics For Clostridium Difficile Disease. The Journal Of The American Medical Association (JAMA) 1994;271(24):1913-1918.

Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 31: 129-134, 1993.

Quinton J F, Sendid B,et al. Anti-Saccharomyces cerevisiae mannan combined with antineutrophil antibodies in inflammatory bowel disease. Prevalence and diagnostic role. Gut 42: 788-791, 1998.

Saint-Marc T, Rossello-Prats L, Touraine J L. [Efficacy Of Saccharomyces Boulardii In The Treatment Of Diarrhea In Aids] [Article In French]. Ann Med Interne (Paris) 1991;142(1):64-5.

Schloterrer M, Bernasconi P, Lebreton F, Wassermann D. Value Of Saccharomyces Boulardii In The Digestive Acceptability Of Continuous-flow Enteral Nutrition In Burnt Patients. Nutrition Clinique Et Metabolique 1987;1:31-34.

Sendid B, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 93: 1306-1310, 1998.

Spirt M J. Antibiotics in inflammatory bowel disease: New choices for an old disease. Am J Gastroenterol 89:974-978, 1994.

Surawicz C M, Elmer G W, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989 Apr;96(4):981-8.

Surawicz C M, Mcfarland L V, et al. J. Treatment Of Recurrent Clostridium Difficile Colitis With Vancomycin And Saccharomyces Boulardii. The American Journal Of Gastroenterology 1989;84(10):1285-1287.

Surawicz C M, Mcfarland L V, et al. The Search For A Better Treatment For Recurent C Difficile Disease: The Use Of High Dose Vancomycin Combined With Saccharomyces Boulardii. Clinical Infectious Diseases 31:1012-1017 (2000).

Tempe J D, Steidel A L, et al. Use Of Saccharomyces Boulardii For The Prevention Of Diarrhea During Continuous Enteral Feeding. Semaine Des Hopitaux De Paris 1983;59(18):1409-1412.

Allergy Research Group®
30806 Santana Street; Hayward, CA 94544
Phone: 800-545-9960 / 510-487-8526
Fax: 800-688-7426 / 510-487-8682
www.AllergyResearchGroup.com

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.